These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 15331922

  • 1. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K, Higuchi K, Okazaki H, Suto R, Hamaguchi M, Tanigawa T, Sasaki E, Shiba M, Watanabe T, Fujiwara Y, Oshitani N, Matsumoto T, Arakawa T.
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ.
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y, Kamano T, Kitajima M, Kawai K, Watabe S, Ochiai T, Sakamoto K, Shirasaka T.
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [Abstract] [Full Text] [Related]

  • 8. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
    Tanaka T, Fujita S, Tanaka N, Ooka M, Okajima S, Tanaka N.
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
    [Abstract] [Full Text] [Related]

  • 9. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y.
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):4913-21. PubMed ID: 15297391
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y, Takanashi Y, Yukawa N, Saeki H, Wada H, Kanari M, Yamada R, Satoh T, Yamamoto N, Imada T.
    Anticancer Res; 2006 Aug 01; 26(2B):1455-62. PubMed ID: 16619558
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T, Tsukuda M, Inuyama Y, Taguchi T.
    Gan To Kagaku Ryoho; 2001 Jun 01; 28(6):855-64. PubMed ID: 11432358
    [Abstract] [Full Text] [Related]

  • 14. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T, Taguchi T.
    Gan To Kagaku Ryoho; 2006 Jun 01; 33 Suppl 1():4-18. PubMed ID: 16897967
    [Abstract] [Full Text] [Related]

  • 15. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M.
    Anticancer Drugs; 1996 Jul 01; 7(5):548-57. PubMed ID: 8862723
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
    Liu HY, Ding L, Yu Y, Chu Y, Zhu H.
    Yao Xue Xue Bao; 2012 Oct 01; 47(10):1363-9. PubMed ID: 23289150
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
    Yasui H, Kawakami T, Kashiwagi H, Mori K, Omae K, Kasai J, Yoshisue K, Kawahira M, Tsushima T, Machida N, Fukutomi A, Yamaguchi K.
    Int J Clin Oncol; 2019 Jun 01; 24(6):660-665. PubMed ID: 31011915
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y.
    Gan To Kagaku Ryoho; 2006 Jun 01; 33 Suppl 1():37-41. PubMed ID: 16897970
    [Abstract] [Full Text] [Related]

  • 20. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
    Yamamoto K, Imamura H, Furukawa H, Kishimoto T, Tanaka J, Oshiro R, Tatsuta M, Masutani S, Fukunaga M, Nakayama T, Takemoto H, Kondo M, Kamigaki S, Kawasaki T.
    Gan To Kagaku Ryoho; 2005 Oct 01; 32(11):1748-51. PubMed ID: 16315929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.